Perioperative Management of Anticoagulants and Platelet Inhibitors for Cutaneous Surgery: A Survey of Current Practice

• Published in: Dermatologic surgery Vol. 28; no. 6; pp. 513 - 517
• Main Authors: Kovich, Olympia, Otley, Clark C.
• Format: Journal Article
• Language: English
• Published: Boston, MA, USA Blackwell Science, Inc 01.06.2002; by the American Society for Dermatologic Surgery, Inc; Blackwell
• Subjects: Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; Anticoagulants - administration & dosage; Aspirin - administration & dosage; Biological and medical sciences; Blood. Blood coagulation. Reticuloendothelial system; Dermatologic Surgical Procedures; Humans; Interprofessional Relations; Medical sciences; Perioperative Care; Pharmacology. Drug treatments; Platelet Aggregation Inhibitors - administration & dosage; Surveys and Questionnaires; Warfarin - administration & dosage; Human; Skin disease; Platelet; Questionnaire; Surgery; Intraoperative; Strategy; Anticoagulant; Mucocutaneous; Inhibitor
• ISSN: 1076-0512; 1524-4725
• DOI: 10.1046/j.1524-4725.2002.12109.x

background. Perioperative management of therapy with anticoagulants or platelet inhibitors for patients having cutaneous surgery presents dilemmas for dermatologic surgeons. objective. To outline the current spectrum of practice for perioperative management. methods. Questionnaires were mailed to 504 dermatologic surgeons. Data included use of warfarin, aspirin, and nonsteroidal anti‐inflammatory drugs (NSAIDs) perioperatively and involvement of other physicians in making management decisions. results. Of the responding physicians, 83% routinely ask primary physicians or cardiologists for recommendations about perioperative management, 80% discontinue warfarin therapy perioperatively at least some of the time, 26% always discontinue aspirin therapy, 38% manage aspirin and NSAIDs in the same manner, and 53% withhold therapy with NSAIDs for less time than with aspirin. conclusion. Dermatologic surgeons use various perioperative management strategies. Despite no published evidence of increased hemorrhagic risk with anticoagulant or platelet inhibitor therapy during cutaneous surgery, many physicians discontinue therapy perioperatively.